Associated Papers
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
Abelman RO et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Mechanism of action of non-camptothecin inhibitor Genz-644282 in topoisomerase I inhibition.
Nishida M et al.
Communications Biology, 2022
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Jo U et al.
Molecular Cancer Therapeutics, 2022
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.
Coates JT et al.
Cancer Discovery, 2021
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
Roy A et al.
Antimicrobial Agents and Chemotherapy, 2009
A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance.
Losasso C et al.
Nucleic Acids Research, 2008
The different cleavage DNA sequence specificity explains the camptothecin resistance of the human topoisomerase I Glu418Lys mutant.
Fiorani P et al.
Nucleic Acids Research, 2006
Select a paper to view details